ELPEN Pharmaceutical Co., Inc.
🇬🇷Greece
- Country
- 🇬🇷Greece
- Ownership
- Private
- Established
- 1965-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.elpen.gr
Clinical Trials
49
Active:5
Completed:30
Trial Phases
5 Phases
Phase 1:1
Phase 2:1
Phase 3:2
+2 more phases
Drug Approvals
10
CIMA_AEMPS:8
PHILIPPINES:2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (33.3%)Not Applicable
1 (16.7%)Phase 1
1 (16.7%)Phase 2
1 (16.7%)Phase 4
1 (16.7%)Administration of Fingolimod in Greek Patients With Multiple Sclerosis.
Not yet recruiting
- Conditions
- Relapsing Remitting Multiple Sclerosis
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT06949956
Real World Study in Greek Patients With BPH for Disease Control and QoL Under FDC Treatment With Solifenacin/Tamsulosin.
Recruiting
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT06528613
- Locations
- 🇬🇷
Second Department of Urology, Sismanoglio Hospital, Athens, Greece., Athens, Greece
🇬🇷Department of Urology, Venizelio General Ηospital, Heraklion, Greece
🇬🇷Department of Urology, General Hospital of Messinia, Kalamata, Greece
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
Completed
- Conditions
- Papillomavirus Infections
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 524
- Registration Number
- NCT06399341
- Locations
- 🇬🇷
University General Hospital of Ioannina, Ioannina, Greece
🇬🇷University General Hospital of Larissa, Larissa, Greece
🇬🇷University General Hospital of Patra, Patra, Greece
QualiTy of Life Evaluation in Patients With ChRonic ObstructIve Pulmonary Disease Who Require Tiotropium as additiOnal treatmeNt.
Not yet recruiting
- Conditions
- COPD
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT06170125
TorasEmide Induced Effect on QoL and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone.
Recruiting
- Conditions
- Chronic Heart Failure
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06117722
- Locations
- 🇬🇷
ATTIKON University Hospital, Athens, Attica, Greece
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
No news found